TC-E5008 is a potent inhibitor of mutant IDH1, exhibiting anti-proliferative activity against multiple ER-positive breast cancer cell lines; it shows high inhibitory potency against the R132H and R132C IDH1 mutants (Ki = 190 nM and 120 nM, respectively) and weak activity against wild-type IDH1 (Ki = 12.3 μM).